# University of Kansas Alzheimers Disease

> **NIH NIH P30** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2022 · $764,017

## Abstract

ABSTRACT
 Most adults with Down syndrome (DS) will develop pathology associated with Alzheimer's disease (AD)
beginning at ~ age 40. By age 65 the cumulative incidence of dementia exceeds 90% and is the leading cause
of death in people with DS. However, individuals with DS have traditionally been left out of many of the national
ADRCs clinical cohorts and are not included in state-of-the-art trials developed to prevent, delay, or treat AD.
 This administrative supplement will support the University of Kansas Alzheimer’s Disease Research
Center’s (KU ADRC) clinical core to develop a Down Syndrome (DS) Cohort, which will increase opportunities
for the study of DS and AD at KU and beyond. Additionally, to advance the KU ADRCs scientific theme of the
role of altered energy metabolism in brain aging and AD, the development of this cohort will allow us to
measure metabolic outcomes (e.g. physical activity, aerobic fitness, body composition, and dietary
assessment) in individuals with DS and support clinical trials testing the therapeutic potential of manipulating
energy metabolism to enable new avenues of research in AD prevention and treatment in individuals with DS.
 Specifically, we will recruit a well characterized sample of 40 adults with DS for enrollment into
collaborating studies. All participants will undergo clinical testing by our clinical core using the NACC DS
module which will allow them to be enrolled in a DS registry and available for enrollment in both national
cohorts and investigator-initiated trials. Secondarily, to prepare for collaboration with national cohorts and
future investigator-initiated trials we will recruit 20 participants from our DS cohort to participate in a trial
readiness cohort where we will collect an expanded cognitive battery, blood sample, and neuroimaging
assessments (MRI, amyloid PET, and tau PET) harmonized to the methods employed in the Alzheimer’s
Biomarker Consortium- Down Syndrome (ABC-DS). Additionally, we will collect metabolic factors such as
physical activity, aerobic fitness, body composition, and dietary intake.
 Creating a dedicated infrastructure and refining our data collection capabilities will enable the KU
ADRC to advance local and national studies in DS and dementia and accelerate new avenues of research into
the role of metabolism in brain aging and AD in the DS patient.

## Key facts

- **NIH application ID:** 10655210
- **Project number:** 3P30AG072973-02S1
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** RUSSELL H. SWERDLOW
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $764,017
- **Award type:** 3
- **Project period:** 2021-08-15 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10655210

## Citation

> US National Institutes of Health, RePORTER application 10655210, University of Kansas Alzheimers Disease (3P30AG072973-02S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10655210. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*